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The ultimate need of “precision  
psychiatry”
Interview with Dr Dina Popovic
Slawomir Murawiec: 
How do you think, what is 
the main problem in devel-
opment of pharmacological 
interventions in psychiatry 
in its history, from the be-
ginning up to now? Do we 
use medication in truly sci-
entific way in the treatment 
of mental disorders? 
Dr Dina Popovic: The 
main issues in modern psy-
chiatry derive from the fact 
that the current diagnos-
tic systems are based on 
clinical symptoms, which 
reflect clinically and etio-
logically heterogeneous 
entities. The currently avail-
able pharmacological treatments were not developed 
based on the understanding of the patophysiological 
bases of psychiatric disorders, as would be expected. 
Rather, they derive from clinical observations and were 
often discovered by chance. A classic example is that 
of lithium, a gold-standard drug for the treatment 
of bipolar disorders. The discovery that lithium dis-
solves urate stones set the scene for its use for a wide 
range of conditions. Lithium water and drinks (such 
as 7-UP), and even health spas specialized in lithum 
waters were industrialized, and supposedly produced 
a sense of well-being. This widespread use of lithium 
led to the discovery by Carl Lange in the 1880s that it 
had prophylactic effects in manic-depressive disorders.
Not only that the drugs were not developed based on 
our understanding of the biological bases of mental 
disorders, the truth lays in the opposite direction; the 
conclusion that alterations of the dopaminergic, sero-
toninergic, noradrenergic and glutamatergic systems 
are implicated in pathogenesis of psychiatric disorders 
derives from the mechanisms of action of drugs that 
were seen to have an effect in their treatment [1].
S.M.: But what can we do with this? Is your group is 
involved in clinical research with the aim to solve this 
fundamental problem?
D.P: In general, medical research aims to improve 
patient care, both through basic and clinical research, 
which converge more and more into ‘translational 
research’. Our group is involved mainly in clinical re-
search, which although it will not give us the answer 
to the causes, for instance, of mental disorders such 
as schizophrenia or major depressive disorder, but may 
give clues to the prevention of serious complications 
such as suicide [2, 3]. 
At the moment, the decision of the most appropriate 
treatment for each patient is often challenging, both 
due to the unclear diagnostic boundaries and the pau-
city of evidence-based logarithms for the treatment 
of psychiatric disorders, including bipolar disorders. 
The trend in other branches of medicine-in particular 
in oncology- is to use “precision medicine” to find 
the most adequate treatment for each patient. Preci-
sion medicine aims to predict disease vulnerability, 
to aid in accurate diagnosis of well-defined disease 
endophenotypes, and to optimize treatment based 
on the individual patients biological characteristics 
[4]. It involves integrating each patients’ genetic and 
epigenetic information, other biomarkers, environ-
mental exposures, and clinical signs and symptoms 
[4]. Also in psychiatry the state-of-art research is 
attempting to progress from blockbuster medicine 
to “stratified” treatment. “Stratified” psychiatry aims 
to bring into line diagnosis, treatment, and pos-
sibly even prevention, with each patient’s genetic 
predisposition [5]. Currently, it was proposed that 
bipolar patients could be stratified according to the 
psychopathological markers, genetics, epigenetics, 
endophenotypes-based on neuropsychology (neu-
rocognition), neuroeconomy, stratification based 
on the presence of comorbidities, stratification 
according to the presence of mixed features and 
according to the predominant polarity. Furthermore, 
staging models have been proposed (life-time stag-
ing, functional staging).
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S.M.: Professor Eduard Vieta published this year in 
Lancet Psychiatry the paper devoted to staging of 
bipolar disorder.
D.P.: Yes. Staging refers to subclassifying illnesses ac-
cording to their progression and implies differential 
treatment interventions as a function of stage of 
illness [6].
 In fact, progressive neural and physical dysfunction 
that we see in bipolar patients after repeated mood 
episodes can be construed as a cumulative state of 
allostatic load. Allostatic load relates to the neural and 
bodily ‘‘wear and tear’’ that emerge in the context of 
chronic stress. The concept of allostatic load can help 
to reconcile cognitive impairment and increased rates 
of clinical comorbidities that occur over the course of 
cumulative episodes [7]. The presumption in staging 
is that early intervention would prevent developing 
mood episodes, disorder severity escalation and physi-
cal and cognitive complications [6].
The progression of BD is staged according to the spec-
trum that presents prodromal stages at one end, and 
refractory clinical presentations, which could culminate 
with persistence of unremitting illness on the other 
end. The staging model has important clinical implica-
tions, proposing early intervention and neuroprotective 
strategies in early phases, while the latter stages may 
require more rehabilitative interventions [7].
Kapczinski et al. [8] have suggested the need to 
include neurobiological parameters/biomarkers, as-
sessment of neurocognition, psychosocial functioning 
and autonomy alongside the longitudinal evaluation 
of clinical variables. This approach will utterly facilitate 
a better understanding of the mechanisms underly-
ing progression of bipolar disorder and ameliorate 
treatment strategies.
S.M.: Could you say something more about that last 
point, that means biomarkers in psychiatry?
D.P.: Biomarkers refer to genes, proteins or other 
molecules, or morphological characteristics, associa-
ted with physiological or biological mechanisms [9]. 
They may be used for defining prognosis and risk of 
developing a disease, monitoring response to treat-
ment, establishing new therapeutic targets and eluci-
dating unclear physiopathological processes [9−11]. 
In bipolar disorder, biomarkers seem to be important 
to evaluate disease activity and progression associated 
with different moods (mood biomarkers), as well as 
to identify specific characteristics of the disease (trait 
biomarkers) [12]. However, at the moment there are 
no valid and reliable biomarkers, and biological cor-
relates are mere expression of neuroprogression [6].
S.M: So we are back in clinic. You are trying to over-
come this difficulty in practice.
D.P: In the attempt to overcome this difficulty, our 
group has attempted to aid clinical decision-making by 
stratifying treatments for the maintenance treatment 
of bipolar disorder according to their relative efficacy 
in preventing depression, mania, or both. The polarity 
index, a measure of the relative prophylactic efficacy of 
drugs or psychological interventions, may be a useful 
tool to guide maintenance treatment according to 
predominant polarity [13, 14], with important clinical 
implications [15]. 
Nonetheless, stratification of treatments for bipolar 
disorders based on biomarkers and improved clinical 
markers are greatly needed to increase the efficacy 
of currently available treatments and improve the 
chances of developing novel therapeutic approaches.
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